Overview

Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in SCI

Status:
Completed

Trial end date:
2020-04-01

Target enrollment:
0

Participant gender:
All

Summary

Neuropathic pain is a common complaint in those with spinal cord injury (SCI) that has a significant negative effect on quality of life. Efficacy of various treatments, however, remains controversial. There is evidence to support that gabapentin and pregabalin have some benefit in reducing neuropathic pain. Gabapentin is effective in the management of symptoms and concerns related to SCI including motor recovery, spasticity, and mood among others. This makes gabapentin an important pharmacologic intervention, which compels providers to define treatment guidelines related to its use. One aspect of which should relate to the timing of initiation of therapy. The goal of this study is to determine whether timing of initiation of treatment with gabapentin will decrease prevalence and intensity of neuropathic pain.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

MetroHealth Medical Center

Treatments:

Gabapentin

Criteria

Inclusion Criteria:

1. Clinical diagnosis of acute spinal cord injury

2. Admission to acute inpatient rehabilitation

Exclusion Criteria:

1. Unable to communicate verbally or by writing, unable to follow basic instructions, or
unable to answer questions regarding their symptoms